Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel (albumin-bound) with Oxaliplatin and S-1 for Gastric Adenocarcinoma Conversion Therapy
NCT04047953Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Sep 2019
- Primary completion
- Dec 2023
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label, single-arm trial of Paclitaxel Micelles for Injection in gastric adenocarcinoma, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: R0 resection rate. Started Sep 2019; status: recruiting.
02
Drugs
Paclitaxel Micelles for Injection
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04047953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047953.